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The distal short consensus repeats 1 and 2 of the membrane
cofactor protein CD46 and their distance from the cell membrane
determine productive entry of species B adenovirus serotype 35
Abstract
The human regulator of complement activation membrane cofactor protein (CD46) has recently been
identified as an attachment receptor for most species B adenoviruses (Ads), including Ad type 3 (Ad3),
Ad11, and Ad35, as well as species D Ad37. To characterize the interaction between Ad35 and CD46,
hybrid receptors composed of different CD46 short consensus repeat (SCR) domains fused to
immunoglobulin-like domains of CD4 and a set of 36 CD46 mutants containing semiconservative
changes of single amino acids within SCR domains I and II were tested in binding and in
Ad35-mediated luciferase transduction assays. In addition, anti-CD46 antibodies and soluble
polypeptides constituting various CD46 domains were used in binding inhibition studies. Our data
indicate that (i) CD46 SCR I or SCR II alone confers low but significant Ad35 binding; (ii) the presence
of SCR I and II is required for optimal binding and transgene expression; (iii) transduction efficiencies
equivalent to that of full-length CD46 are obtained if SCR I and II are at an appropriate distance from
the cell membrane; (iv) ablation of the N-glycan attached to SCR I has no influence on receptor
function, whereas ablation of the SCR II N-glycan results in about a two- to threefold reduction of
binding and transgene expression; (v) most putative Ad35 binding residues are located on the same
solvent-exposed face of the SCR I or SCR II domain, which are twisted by about 90 degrees ; and (vi)
the putative Ad35 binding sites partly overlap with the measles virus binding surface.
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The human regulator of complement activation membrane cofactor protein (CD46) has recently been
identified as an attachment receptor for most species B adenoviruses (Ads), including Ad type 3 (Ad3), Ad11,
and Ad35, as well as species D Ad37. To characterize the interaction between Ad35 and CD46, hybrid receptors
composed of different CD46 short consensus repeat (SCR) domains fused to immunoglobulin-like domains of
CD4 and a set of 36 CD46 mutants containing semiconservative changes of single amino acids within SCR
domains I and II were tested in binding and in Ad35-mediated luciferase transduction assays. In addition,
anti-CD46 antibodies and soluble polypeptides constituting various CD46 domains were used in binding
inhibition studies. Our data indicate that (i) CD46 SCR I or SCR II alone confers low but significant Ad35
binding; (ii) the presence of SCR I and II is required for optimal binding and transgene expression; (iii)
transduction efficiencies equivalent to that of full-length CD46 are obtained if SCR I and II are at an
appropriate distance from the cell membrane; (iv) ablation of the N-glycan attached to SCR I has no influence
on receptor function, whereas ablation of the SCR II N-glycan results in about a two- to threefold reduction
of binding and transgene expression; (v) most putative Ad35 binding residues are located on the same
solvent-exposed face of the SCR I or SCR II domain, which are twisted by about 90°; and (vi) the putative Ad35
binding sites partly overlap with the measles virus binding surface.
The species B serotypes of human Adenoviridae account for
about 34% of all adenovirus (Ad) isolates typed and reported
to the World Health Organization, second to species C Ads,
which account for about 50% of the isolates (65). Species B
Ads are divided into B1 serotypes, including Ad type 3 (Ad3),
Ad7, Ad16, Ad21, and Ad50, which predominantly infect the
upper respiratory tract, and the B2 serotypes, including Ad11,
Ad14, Ad34, and Ad35, which are associated with kidney and
urinary tract infections (56, 65). Whereas species B1 Ads are
commonly isolated, species B2 Ads account for fewer than 1%
of the reported Ad isolates, with a seroprevalence of "5% for
Ad11, Ad34, and Ad35 and 15 to 20% for Ad14 in a typical
Western population (64). However, like all human adenovi-
ruses, Ad11, Ad34, and Ad35 are frequently isolated from
patients with compromised immune systems, such as AIDS
patients or renal or bone marrow transplant patients (36).
Recently, recombinant species B Ads or fiber-swapped Ad
vectors in which the fiber protein of the commonly used Ad5 is
swapped with species B Ad fiber have gained interest for use in
gene therapy and vaccination approaches. An important rea-
son for the latter, besides the low seroprevalence of these
viruses, which should allow accurate dose control, is that B Ads
were suggested to bind to a different cell surface receptor (9,
11, 19, 52, 63). Accordingly, recombinant species B Ads (54,
64) or fiber-swapped Ad vectors (23, 24, 29, 51, 61) have an
extended tropism compared to species C vectors and are able
to efficiently infect hematopoietic and dendritic cells. Using
different approaches, CD46 has been identified as an attach-
ment receptor for species B Ad3 (62), Ad11 (59), and Ad35
(18). Additional viruses that bind to CD46 include species D
Ad37 (70), the Edmonston strain of measles virus (MV) (12,
49), human herpesvirus 6 (55), and bovine viral diarrhea virus
(42). In addition, CD46 has been reported to bind different
bacteria (33). CD46 belongs to a family of regulators of com-
plement activation (RCA), whose biological role is to prevent
complement activation on autologous tissue by binding C3b
and C4b and by acting simultaneously as a cofactor for the
proteolytic factor 1 (34). Recent evidence also suggested an
additional role in linking innate and acquired immunity by
signaling events induced in macrophages and lymphocytes (re-
viewed in reference 53).
CD46 consists of (i) four amino-terminal copies of an ap-
proximately 60-amino-acid structural motif termed the short
consensus repeat (SCR) (also called complement control pro-
tein repeat), (ii) one to three serine-threonine-proline-rich
(STP) domains, (iii) a short region of unknown function, (iv) a
transmembrane spanning domain, and (v) a carboxy-terminal
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cytoplasmic tail. Alternative splicing of the STP domain-en-
coding exons (STABC) and cytoplasmic tail exons (CYT1 and
CYT2) gives rise to the four major splice variants C1, C2, BC1,
and BC2 and to additional minor variants (34). Each SCR
module is predicted to be about 35 Å long and to form a
five-stranded #-barrel structure. Domains SCR I, SCR II, and
SCR IV each contain one N-linked oligosaccharide, and the
STP domains contain O-linked glycans. For MV, N-linked
oligosaccharides do not participate in direct binding, although
the sugar attached to N80 in SCR II was shown to be essential,
suggestive of a stabilization function (37, 39, 46).
An increasing number of virus receptor binding sites are
being defined at the molecular and structural levels, an impor-
tant prerequisite to infer links between receptor binding and
mechanisms of pathogenesis (58, 66, 67). Also, the superior
gene transfer performance of serotype B fiber-containing vec-
tors, in particular those of Ad35, underscores the importance
of characterizing the molecular sites involved in binding of
Ad35 to CD46 in more detail. To this end, a series of CD46
hybrid receptors consisting of different CD46 SCR domains
and CD4 immunoglobulin (Ig)-like modules (5, 46) were used
to assess Ad35 binding and Ad35-mediated transgene expres-
sion. To further define residues involved in Ad35 binding, a set
of 36 CD46 mutants containing semiconservative changes of
single amino acids within the SCR I and II domains (4) were
tested. The results from these analyses were complemented
with binding inhibition studies using anti-CD46 antibodies and
soluble polypeptides comprising various CD46 domains.
MATERIALS AND METHODS
Cells, viruses, and screening with fiber-chimeric viruses. The A549 human
lung carcinoma cell line was received from P. Sonderegger (Biochemical Insti-
tute, University of Zu¨rich). The mouse fibroblast cell line Ltk$ and melanoma
cell line B16-F1 were received from J. Pavlovic (Medical Virology, University of
Zu¨rich). The baby hamster kidney cell line BHK-21 was provided by M. Bach-
mann (Cytos Biotechnology, Schlieren-Zu¨rich, Switzerland). All cells, including
simian COS7 cells and human embryonic retinoblast 911 cells (16) and PER.C6
cells (15), were grown in Dulbecco’s modified Eagle’s medium plus 10% fetal
bovine serum (FBS). The B16-CD46 cell line, stably expressing the BC1 splice
isoform, was generated as described for BHK-CD46 cells (62).
Ad35 was radiolabeled as described for Ad2 (21, 48). Briefly, A549 cells were
grown in 10-cm-diameter petri dishes to 90% confluency and wild-type (wt) Ad35
(64) was inoculated at a multiplicity of infection (MOI) of 10. At 10 hours
postinfection (p.i.), the virus-containing medium was replaced by a labeling
medium (Dulbecco’s modified Eagle’s medium, 10% dialyzed fetal calf serum,
150 %Ci [3H]methylthymidine per plate [TRK686; Amersham]). Virus was har-
vested at complete cytopathic effect, 36 to 48 h p.i., and released from cells by
three freeze/thaw cycles, Freon extraction, and two CsCl gradient ultracentrifu-
gations. Specific activity (2.6 & 10$5 cpm/viral particle [vp]) was determined by
scintillation and measurement of viral proteins, with the assumption that 4& 109
vp correspond to 1 %g protein.
To study whether the Ad5 fiber-chimeric viruses carrying the B group fiber 7,
11, 16, 35, or 50, and the C group fiber 5 as a control (24), make use of CD46,
an infection experiment was performed with the B16-CD46 cell line and its
parental control. Infection was performed on 1 & 105 cells/well in a 24-well
format with the Ad5 fiber-chimeric viruses carrying the luciferase transgene for
2 h at an MOI of 1,000 vp/cell. At 48 h postinfection, cells were lysed with a lysis
buffer containing 1% Triton X-100, and luciferase expression was measured with
a luciferase assay system (Promega) on a Luminoskan Ascent instrument
(Thermo Labsystems).
Blocking of Ad35 binding. Blocking experiments were performed as described
previously (62). Briefly, BHK-CD46 cells were detached with phosphate-buffered
saline (PBS)–20 mM EDTA, and 5 & 105 cells were incubated with monoclonal
antibodies specific for CD46, control anti-human coxsackievirus B and Ad re-
ceptor (CAR) antibody E1-1, or soluble CD46 domain-containing polypeptides
or with a 30-fold excess of unlabeled Ad35 on ice for 30 min. Subsequently, 0.3
%g of [3H]Ad35 was added to about 5 & 105 cells in a total volume of 200 %l on
ice for 1 h (corresponding to 2,500 vp/cell). Cells were washed and analyzed for
bound virus by using liquid scintillation counting. The data were normalized to
the amounts of virus bound in the absence of inhibitors and represented as the
average and standard deviation from three independent experiments. Statistical
evaluation was performed using Student’s t test.
Construction of the soluble CD46ex-Fc has been described earlier (62).
CD46ex-Fc comprises 295 amino acids of the mature extracellular domain,
including the SCR I to IV domains, the STP of BC1, and the short region of
unknown function, fused to the 232 amino acids of the human IgG1-Fc domain
including the hinge, CH2, and CH3 regions. The CARex-Fc protein comprises
the extracellular domain of coxsackievirus B and the Ad receptor (14). Expres-
sion and purification of CD46 proteins encompassing the SCR I domain (CD46-
SCR I), the SCR I and II domains (CD46-SCR I-II), the SCR I to IV domains
(CD46-SCR I-IV), and the whole extracellular CD46 domain of the BC splice
form (CD46-BC) were similarly performed. Boundaries of SCR domains were
adopted as described by Lublin et al. (35). As a starting expression vector a
modified pcDNA3 (Invitrogen) was used, in which the endogenous cytomegalo-
virus promoter was replaced by the cytomegalovirus immediate-early promoter
plus intron A from pVR1012 (44) and in which the influenza virus hemagglutinin
signal peptide consisting of 15 amino acids followed by His6 tag, a spacer, and the
rTEV cleavage site (Invitrogen) had been introduced. The signal peptide-cleaved
form of CD46-SCR I was expected to consist of 82 amino acids, including the
N-terminal 20 amino acids of the His tag, spacer, and cleavage site and 62 amino
acids of SCR I. Similarly, signal peptide-cleaved forms of CD46-SCR I-II, CD46-
SCR I-IV, and CD46-BC consisted of totals of 145, 272, and 315 amino acids,
respectively. All proteins were expressed in simian COS cells and purified from
cell supernatants by using Ni-nitrilotriacetic acid agarose (QIAGEN AG, Basel,
Switzerland). The concentrations of purified proteins were determined by bicin-
choninic acid assay (Pierce) using bovine serum albumin as a standard. The
purity of all proteins was judged to be '90% when analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and Coomassie blue staining.
Binding and transgene expression using hybrid CD46-CD4 proteins. Gener-
ation of the 17 expression constructs encoding hybrid CD46-CD4 proteins was
described previously (5, 46, 57). All chimeric proteins contained the CD46 leader
peptide and were membrane anchored via the transmembrane sequence of CD4
(also the I-II and I-IV constructs). In all constructs, a 5-amino-acid-long glycine-
rich peptide separated the CD46 and CD4 parts, allowing for structural flexibil-
ity. The two constructs I-II/4 dg1 and I-II/4 dg2 contained single point mutations
N49Q (I-II/4 dg1) and N80Q (I-II/4 dg2), deleting the N-glycosylation site con-
tained in each of these domains. The I!II;I/4 and I!I;II/4 constructs contained
duplicated and exchanged intracysteine segments, encompassing SCR I plus T64
to I92 of the SCR II domain fused to C30 to E63 of SCR I in the first construct
and SCR I fused to C1 to K30 of SCR I and C93 to V126 in the second. Likewise,
all 36 CD46 single point mutants and one 6-amino-acid exchange mutant, P39-
T44, containing six alanines replacing the endogenous sequence, were described
earlier (4, 30). These constructs were based on the C2 splice isoform of CD46
and thus contained all four SCR domains.
Mouse Ltk$ cells were grown in 10-cm-diameter petri dishes to 70 to 90%
confluency and were transiently transfected using the vaccinia virus T7 expres-
sion system (17). Cells were infected with vaccinia virus VTF7-3 at an MOI of 10
to 15 for 40 min. The virus was removed, and cells were transfected with 25 %g
of plasmid DNA encoding the different CD46 constructs and 33.5 %l Lipofectin,
using the protocol of the manufacturer (Gibco-BRL, Paisley, United Kingdom).
The cells were harvested about 20 h after transfection by being detached from
the dish by PBS-EDTA treatment. After being washed twice with balanced salt
solution (BSS)–2% FBS, the cells were aliquoted for cytometric analysis (see
below), binding assay, or transgene expression experiments. For binding assays
3.5 & 105 to 5 & 105 cells were incubated with radiolabeled virus as described
above. For transgene expression 5 & 105 cells/well were seeded in 12-well plates
and allowed to attach for at least 5 h, followed by addition of 2500 vp/cell of
Ad35.(E3.Luc (64). At 24 h p.i. cells were harvested, and luciferase activity was
determined as described above. The luciferase activities were normalized to the
lysate protein concentration. Binding efficiencies and transgene expression levels
were obtained by dividing binding values (counts per minute of bound [3H]Ad35
minus counts per minute of cells alone) or transgene expression levels (relative
light units of infected cells minus relative light units of cells alone) by the levels
of hybrid surface expression. All measurements, including surface expression
analysis, were done in triplicates and repeated at least three times.
Antibodies and flow cytometric analysis. CD46 SCR I-specific antibodies in-
cluded E4.3 (PharMingen, Basel, Switzerland), MCI20.6 (49), 13/42 (BMA Bio-
medicals AG, Augst, Switzerland), Tra-2.10 (1), and MEM-258 (Serotec Ltd,
Oxford, United Kingdom). The SCR II-specific antibody M177 was purchased
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from HyCult Biotechnology, Uden, The Netherlands, and the SCR III/IV-spe-
cific antibody GB24 (1) was a generous gift from J. Atkinson, Washington
University School of Medicine. Cell surface expression of the chimeric proteins
was determined by using the SCR I-specific antibody E4.3 for all constructs
containing SCR I or the SCR II-specific M177 for the two hybrids encoding only
SCR II. CD46 single point mutants and the one 6-amino-acid exchange mutant
P39-T44 were all quantified using the E4.3 antibody, except construct E2A,
which was measured using M177. Mutant CD46 expression levels were in the
range of 50 to 130% of wt CD46 expression, except for the II/4 and II!II/4
constructs, which yielded only about 10% and 20% of the wt CD46 expression
level, respectively. Control-antibody for E1-1 anti-CAR was described previously
(14). Secondary fluorochrome conjugates sheep anti-rabbit and goat anti-mouse
IgG-phycoerythrin were purchased from Serotec, Oxford, United Kingdom.
For cytofluorometric analysis of adherent cells, subconfluent cells were washed
with PBS and detached by treatment with PBS–20 mM EDTA. About 2 & 105
cells were incubated with 1 %g of antigen-specific antibodies in 250 %l of BSS
(0.14 M NaCl, 1 mM CaCl2, 5.4 mM KCl, 0.8 mM MgSO4, 0.3 mM NaH2PO4,
and 0.4 mM KH2PO4, pH 6.9) containing 5% FBS on ice for 30 min. Cells were
washed by pelleting in BSS–2% FBS, incubated with 1 %g of phycoerythrin-
labeled secondary conjugates, and washed again before cytofluorometric analysis
(Cytomics FC 500; Beckman Coulter, Fullerton, CA) was performed with 10,000
viable cells per sample. Background staining of mock-infected and -transfected
mouse Ltk$ cells was measured and subtracted from mean values of CD46
staining obtained from hybrid-expressing cells. Measurements were done in
triplicate.
RESULTS
Chimeric adenoviruses carrying B group fibers use CD46 as
a receptor. We first confirmed and extended observations that
CD46 serves as a receptor for a variety of species B Ads by
inoculating parental mouse B16 cells or B16 cells stably ex-
pressing the BC1 splice form of CD46 (B16-CD46) with Ad5-
based fiber-chimeric viruses harboring the fibers of Ad5, -7,
-11, -16, -35, or -50 (24). CD46 expression had no effect on
species C Ad5 fiber-based transgene expression, but the chi-
meric viruses containing the species B fibers yielded a robust 2-
to 3-log increase of transgene expression in B16-CD46 cells
compared to the parental cells (Fig. 1). Of note, fibers of
serotypes belonging to species B1, including Ad 7, -16, and -50,
as well as B2 serotypes, including Ad11 and -35, revealed a
strong expression increase.
Antibody- and SCR domain polypeptide-mediated blocking
of Ad35 binding to CD46. To identify which SCR domains are
involved in Ad35 binding to CD46, seven different monoclonal
antibodies with specificity for individual SCR domains were
tested for their ability to inhibit binding of [3H]Ad35 to CD46,
as reported previously for Ad3 (62). BHK cells expressing the
BC1 form of human CD46 were first incubated with monoclo-
nal antibodies at various concentrations, followed by addition
of [3H]thymidine-labeled Ad35 and determination of cell-as-
sociated virus by liquid scintillation counting (Fig. 2A). The
two SCR I-specific monoclonal antibodies 13/42 and MEM-
258, as well as the SCR II-specific M177, strongly inhibited
virus binding in a concentration-dependent manner (Fig. 2A
and B). Of note, as determined by analysis of binding to CD46
hybrid constructs, MEM-258 binds to an epitope of SCR I
(data not shown) and not SCR IV, as suggested by the man-
ufacturer’s information. The SCR III/IV-specific antibody
GB-24 inhibited binding at an intermediate level of about 30%
at the highest concentrations used. Finally, the three SCR
I-specific antibodies E4.3, MCI20.6, and Tra-2 had significant
but weak effects on Ad35 binding of 16%, 17%, and 21%
inhibition, respectively, whereas the anti-CAR control anti-
body E1-1 had no significant effect on Ad35 binding (Fig. 2A
and B). Together, these data suggest that mainly SCRs I and II
are potentially involved in Ad35 binding.
Since the blocking data obtained thus far hinted that both
the SCR I and SCR II domains were involved in Ad35 binding,
we performed further binding experiments using soluble
polypeptides carrying various CD46 domains. These proteins
included CD46ex-Fc (62), which forms a dimeric protein con-
taining two CD46 binding sites (similar to CARex-Fc, which
leads to Ad5 aggregate formation through multivalency [14, 43;
unpublished data]); soluble CD46-BC, comprising all four
SCR domains plus the STP domains B and C; and four shorter
polypeptides spanning the SCR I-IV, SCR I-II, and SCR I
domains. Additional constructs encoding the SCR II domain
or the SCR III-IV domains yielded only small protein amounts
and could not be included in our analyses. We found that the
soluble CD46ex-Fc protein inhibited binding of Ad35 to BHK-
CD46 in a dose-dependent manner, with 20 %g/ml giving rise
to 95% inhibition, whereas the control CARex-Fc protein had
no significant effect on Ad35 binding (Fig. 2C). In the cases of
CD46-BC, CD46-SCR I-IV, and CD46-SCR I-II, amounts
equimolar to that of CARex-Fc gave 90%, 88%, and 76%
binding inhibition, respectively. In contrast, CD46-SCR I did
not inhibit Ad35 binding. These data show that at least SCR II
is needed for Ad35 binding.
Mapping Ad35 binding domains with hybrid CD46-CD4
proteins. To map the molecular sites involved in binding of
Ad35 to CD46, a set of 17 hybrid receptors consisting of dif-
ferent CD46 SCR domains and CD4 Ig-like modules (5, 46)
were used. Using a first set of four constructs, we tested bind-
ing and transduction efficiencies mediated by the four SCR
domains fused to increasing numbers of CD4 Ig-like domains.
The CD4 domains act as spacers, increasing the distance be-
tween the potential Ad35 binding site and the plasma mem-
brane. Cells expressing the complete CD4 protein did not
confer Ad35 binding (data not shown). The construct I-IV
lacked the 43-amino-acid stretch including the serine/threo-
nine-rich domains B and C and the short region of unknown
FIG. 1. CD46-expressing cells infected by chimeric adenoviruses
carrying B group fibers. Parental mouse B16 melanoma cells or stably
transfected B16-CD46 cells expressing the BC1 splice form were in-
cubated for 2 h with luciferase-expressing Ad5-Luc or Ad5-chimeric
viruses at an MOI of 1,000 vp/cell. Cells were washed, and transgene
expression was analyzed 2 days p.i. Luciferase activity is expressed in
relative light units.
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function UN. Constructs I-IV/4, I-IV/3-4 and I-IV/4/1-4 con-
tained one, two, or four additional CD4-like Ig domains, re-
spectively, where the roman numerals indicate the SCR do-
mains and arabic numerals the CD4 domains. Single SCR
domains have a size similar to that of Ig domains, and each Ig
domain is expected to increase the distance to the membrane
by about 30 Å (3). All four constructs bound virus with similar
efficiencies, although I-IV/3-4 was slightly more efficient at
virus binding (Fig. 3A). These results confirmed that the mem-
brane-proximal stretch of 43 amino acids does not substantially
influence virus binding. Interestingly, transgene expression var-
ied drastically with the receptor length. Deletion of the BC
sequence (43 amino acids) reduced transgene expression by
about 50%. In contrast, increasing the receptor length by one
or two Ig modules increased transgene expression about five-
fold, and the insertion of four Ig domains (construct I-IV/1-4)
resulted in a threefold increase of transgene expression.
The second set of CD4-CD46-SCR hybrid constructs con-
tained the two outer SCR domains SCR I-II, either alone (I-II)
or fused to increasing numbers of CD4 Ig domains (I-II/4,
I-II/3-4, and I-II/1-4). Two additional constructs including the
I-II/4-type construct also contained the single point mutations
N49Q (I-II/4 dg1) and N80Q (I-II/4 dg2), ablating the N-
glycosylation sites of these domains. Remarkably, the CD46
SCR I-II domain added N terminally to CD4 domains 1 to 4
(construct I-II/1-4) yielded virus binding similar to that of
CD46-expressing cells (Fig. 3B). The deletion of CD4 Ig-like
domains (construct I-II/4 or I-II) yielded about 65% and 25%
of wt CD46 binding, respectively, suggesting an important role
of the CD4 spacer domains. Like for the previous SCR I-IV
constructs, increasing receptor length in the SCR I-II con-
structs was paralleled by increased transgene expression,
reaching a maximum of threefold (construct I-II/3-4) over that
for CD46 alone. Ablation of the SCR I N-linked glycosylation
did not significantly affect virus binding, whereas ablation of
the SCR II N-linked glycosylation resulted in about a twofold
FIG. 2. Inhibition of Ad35 binding to CD46 by anti-CD46 antibodies and SCR domain polypeptides. (A) Ad35 binding inhibition by
CD46-specific antibodies. BHK-CD46 cells were incubated with the indicated CD46-specific antibodies, control anti-CAR antibody E1-1, or a
30-fold excess of cold Ad35, followed by the addition of [3H]Ad35 at 4°C. Virus binding was measured by liquid scintillation counting. The data
were normalized to the amounts of virus bound in the absence of inhibitors and are represented as averages and standard deviations for triplicate
determinations. The asterisks indicate the level of significance (P " 0.05 [single asterisk] and P " 0.005 [double asterisk] for comparison with the
E1-1 negative control). (B) Summary of binding inhibition data with monoclonal antibodies. Percentage of residual binding is depicted as follows:
'90%,!; 76 to 90%,!" ; 51 to 75%,!" ; "25%,". Amino acid residues mainly involved in antibody binding sites and their positions
are indicated. For further details see Fig. 5 and reference 4. (C) Ad35 binding inhibition by SCR domain polypeptides. BHK-CD46 cells were
incubated with the indicated SCR domain polypeptides or control CARex-Fc, followed by the addition of [3H]Ad35. For the lower five
measurements, equimolar amounts of the different proteins were applied. The subsequent processing was as described for panel A.
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binding reduction (P ) 0.005) compared to construct I-II/4.
Transgene expression in these two mutants reached an effi-
ciency similar to that in CD46 wt cells, as reflected by similar
amounts of virus binding and transgene expression, but was
clearly lower than that in the similarly sized I-II/4 construct.
Taken together, the data suggest that SCR I and II are suffi-
cient for Ad35 binding and transgene expression. Moreover,
the distance of these domains from the plasma membrane
strongly influences transgene expression efficiency.
Using another set of seven constructs, we asked whether
SCR I or SCR II alone confers Ad35 binding (Fig. 3C). In-
cluded as controls were CD46- and I-II/4 construct-expressing
cells. Two of the tested constructs, I/4 and II/4, contained
single SCR I and SCR II domains joined to the fourth CD4
Ig-like domain, resulting in a receptor length similar to that of
the I-II construct. Virus binding to and transgene expression in
cells expressing construct I or II fused to domain 4 of CD4
were not significantly different from those of cells expressing
the I-II construct without CD4 domains (Fig. 3B). It should be
noted that the large variation of the values for II/4 resulted
from the unusually low expression levels seen with this con-
struct. Likewise, the extended I!I/4 and II!II/4 constructs
containing duplicated SCR I or SCR II domains were not
significantly different from the constructs containing only one
of these domains.
Finally, the two constructs I!II;I/4 and I!I;II/4, containing
duplicated and exchanged intracysteine segments, and con-
struct II!I/4, with an inverted order of the SCR I and SCR II
domains, were tested. It is notable that the I!II;I/4 construct
carries an additional N-linked sugar in the SCR II domain,
whereas the I!I;II/4 construct is devoid of an N-linked sugar in
its second SCR domain. Both binding and transgene expres-
sion of the I!II;I/4 construct were strongly reduced, to 5 and
6%, respectively, compared to the values for full-length CD46.
The values obtained with the I!I;II/4 as well as with the II!I/4
construct were in the range of those with the other constructs
tested in this series. In summary, the results suggest that the
two N-terminal domains SCR I and II are sufficient for Ad35
binding and transgene expression and that binding was not
confined to a single SCR domain. In addition, binding and viral
transgene expression critically depended on the length of the
FIG. 3. Ad35 binding efficiencies and transgene expression medi-
ated by CD46-CD4 hybrid proteins. Proteins were transiently ex-
pressed in Ltk$ cells by using the VV-T7 system. CD46 surface ex-
pression levels of the various CD46-CD4 hybrid constructs were
normalized to the surface expression levels of CD46-BC1 (data from
one representative experiment). Binding efficiencies were calculated
by dividing the [3H]Ad35 binding values by surface expression levels
and are shown in relation to that of the CD46-BC1 standard. Likewise,
luciferase transgene expression measured by infection of the CD46-
expressing cells with Ad35.(E3.Luc at 24 h posttransduction was de-
termined by normalizing to protein concentration and surface expres-
sion of the CD46 proteins, attributing 100% to the BHK cells
expressing CD46 (BC1). Measurements were done in triplicate and
repeated at least three times. Schematics indicate the following: SCR
I, black; SCR II, crosshatched; SCR III, light grey; and SCR IV, white.
The CD4 Ig-like domain is drawn as a loop. N-linked oligosaccharides
of SCR domains are indicated, whereas the single oligosaccharide of
the CD4 Ig-like domain is omitted, as this sugar is present in all
constructs. (A) Function of four hybrid proteins containing SCR I-IV
fused to increasing numbers of CD4 Ig-like domains. (B) Function of
six hybrid proteins containing SCR I-II fused to increasing numbers of
CD4 Ig-like domains or combined with mutations ablating N-linked
oligosaccharide in SCR I (dg1) or SCR II (dg2). (C) Function of seven
hybrid constructs consisting of single SCR domains, or containing
duplicated or exchanged intracysteine segments, fused to a constant
CD4 Ig-like domain.
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receptor and hence on the distance of the SCR I and II do-
mains from the membrane.
Mapping Ad35 binding residues with 36 single-amino-acid
SCR I-II mutant proteins. To define residues involved in Ad35
binding, a set of 36 CD46 mutants containing semiconservative
changes of single amino acids within the SCR I-II domains
were tested (4). These mutations concerned residues predicted
to be on the CD46 SCR I-II solvent-exposed surface (46) and
consisted of replacements by small residues (alanine for
charged and polar residues and serine for apolar residues).
The use of such semiconservative changes is expected to be
well tolerated and to have a minimal impact on protein con-
formation. Also included was a 6-amino-acid exchange mutant,
P39-T44, containing six alanines replacing the endogenous se-
quence. This loop exchange was suggested to induce a confor-
mational change, which resulted in loss of MV hemagglutinin
binding and a complete or partial loss of binding of antibodies
specific for SCR I (4). Analysis of Ad35 binding and transgene
expression was performed as for the hybrid constructs and is
summarized in Fig. 4. Among the 19 mutant CD46 proteins
with alterations in the SCR I domain, a weak but significant
binding reduction was found for the K15A, E24A, R25A, and
FIG. 4. Ad35 binding efficiencies mediated by 36 single-amino-acid SCR I-II mutant proteins. (A) Nineteen single-amino-acid mutants plus the
exchange mutant P39-T44, containing six alanines replacing the endogenous sequence localized in SCR I, were analyzed as described for Fig. 3.
(B) Seventeen single-amino-acid mutants of SCR II were similarly analyzed. The asterisks indicate the level of significance (P " 0.05 compared
to wt CD46).
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K29A mutations, with 22%, 36%, 22%, and 20% decreases in
binding, respectively. These residues are situated on the same
face of the SCR I solvent-exposed surface as the epitopes
characterized by antibodies 13/42, with some of them contig-
uous (Fig. 5A). Interestingly, the mutant P39-T44, which had
almost completely lost binding of several CD46 SCR I anti-
bodies, including 13/42, as well as binding of MV hemaggluti-
nin or whole MV, had only a marginal Ad35 binding loss (P )
0.05). A 45% reduction of Ad35 binding was monitored with
the Y97A mutant, whose mutation resides in the lower half of
the SCR II domain. Five further mutant sites demonstrated
reduced binding in the range of 20 to 30%, including Q88A,
N94A, Y98A, Y106A, and K119A. Of note, residues Q88, Y98,
K119, and Y106 together with the antibody M177 epitope R69
are situated on a SCR II face that is twisted by about 90°
compared to the SCR I binding surface (Fig. 5D and A, re-
spectively). In contrast, N94 and Y97 are located on the op-
posite side of this face. Reduction of virus binding was accom-
panied by lower transgene expression in several but not all
constructs.
DISCUSSION
A common feature of proteins with SCR domains is that
they recognize virus particles through two or more of those
domains. Thus, our findings that the two N-terminal domains
of CD46 are sufficient for Ad35 binding is in line with the
results obtained from studies of other pathogen RCA receptor
interactions. For example, complement regulatory protein
CR2/CD21, containing 15 or 16 tandemly arranged SCR do-
mains, binds Epstein-Barr virus with its two external SCR
modules (45). The three SCR II-IV modules of CD55, the
FIG. 5. Localization of Ad35 (A to D) or MV hemagglutinin (E to H) binding to the CD46 SCR I-II structure. Four views, each twisted by 90°,
of a space-filling drawing of the CD46 SCRI-II structure (6) were prepared with the program MOLMOL (31), using the Brookhaven protein data
bank (code 1ckl). Data for MV binding sites are taken from references (4, 25, 40, and 46). Light blue, SCR I; dark blue, SCR II; green, N-glycans;
light brown, residues involved in antibody binding of 13/42 (SCR I) and M177 (SCR II); pink, 80% to 100% loss of MV binding in ER24/25AA
and P39-44T mutant; red and dark yellow, 31% to 50% and 20% to 30% loss of binding in single point mutants, respectively; bright yellow, binding
stretches defined by peptide inhibition studies for MV. For details, see the text.
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closest known relative to CD46, were identified as binding sites
for echovirus 7 (7). For CD46 and MV, the two membrane-
distal domains SCR I-II are sufficient for hemagglutinin bind-
ing, but virus particle attachment is enhanced by SCR III and
IV domains (4, 5, 10, 26, 41). Human herpesvirus 6 binds to the
SCR II and III domains (22). Finally, binding of Neisseria
gonorrhoeae pili to host cells depends on determinants in the
SCR III and STP regions (27), whereas the M protein of group
A streptococci promotes adhesion to keratinocytes via SCRs
III and IV (20). Interestingly, in many cases, the binding sites
of the pathogen are different from, or overlap only partially
with, the binding site of the natural ligand (1, 20, 41, 50).
As both Ad35 and MV bind to CD46 SCR I-II, it is con-
ceivable that these unrelated viruses share common binding
areas. Our data revealed common binding features but also
clear differences between the bindings of Ad35 and MV to
CD46 (Fig. 5). Binding inhibitions of the CD46-specific mono-
clonal antibodies commonly used in studies of both viruses
revealed similar rankings. For binding inhibition of Ad35, an-
tibodies 13/42 and M177 showed the strongest effect, GB24 an
intermediate effect, and E4.3, MCI20.6, and Tra-2 a weak
effect. Inhibition of MV soluble hemagglutinin (sH) binding
was strongly inhibited by the antibodies 13/42 and M177,
whereas MCI20.6 and Tra-2 showed a moderate effect and
E4.3 and GB24 a weak effect (4). Thus, for both viruses, anti-
bodies 13/42 and M177 had the strongest blocking effect,
whereas the rankings of the other antibodies were exchanged.
Antibodies may exert a long-distance steric effect, as the
distance between the two antigen-binding paratopes may vary
between 150 Å in a relaxed conformation and 50 Å in a fully
compressed conformation. The buried antigen area making
contact with the antibody binding site consists of 560 to 855 Å2,
as determined from crystal structures of antibody/protein com-
plexes (8). In comparison, virus receptor surface areas bury
about a two- to threefold larger surface area (2, 6, 32). It has
been proposed that strongly inhibiting monoclonal antibodies
directly compete for the virus binding site, while the others
indirectly hinder the virus receptor (4). This suggests that the
two individual epitopes recognized by 13/42 and M177 are
contained within the binding areas of both viruses. The binding
site of 13/42 was not unequivocally mapped but was tentatively
located on the front side below or adjacent to the epitopes of
E4.3, MCI20.6, and Tra-2, including the residues D27, K31,
and H43 and the P39-T44 loop (Fig. 5) (4). It is unknown if the
MEM-258 antibody affects MV binding. The mutation R69A
resulted in a complete loss and mutations D70A and E103A in
a partial loss of SCR II-specific antibody M177 binding, indi-
cating that at least R69 is contained within the epitope recog-
nized by M177. Even if both viruses bind to the 13/42 epitope
on SCR I and the M177 epitope on SCR II, the loop mutation
P39-T44 has a detrimental effect on MV but only a weak effect
on Ad35 binding, suggesting that binding to this particular
region is not shared by the two viruses.
The comparisons of Ad35 and MV sH binding to CD46
single point mutants corroborated this general conclusion but
revealed subtle differences. For Ad35 we found a robust re-
duction of 45% for mutation Y97A and weaker reductions in
the range of 20 to 30% for mutations K15A, R25A, K29A
Q88A, N94A, Y98A Y106A, and K119A. Binding of MV sH
was inhibited by the mutation P39A (50%) and by the muta-
tions E11A and K29A in SCR I and D70A in SCR II (25 to
50%) (4). Another study by Hsu et al. indicated that the double
mutation ER24/25AA (adapted numbering) even reduced
binding of MV to 20% (25). In addition, peptide inhibition
studies combined with genetic modifications over longer
stretches indicated that residues 45 to 48 and 94 to 97 are
critical for MV binding (40, 46). Thus, only one mutation,
K29A, resulted in equivalent reductions of binding to both
viruses. The differential sensitivity of Ad35 and MV for binding
to the N-glycan ablation mutant I-II/4 dg2 indicated an addi-
tional difference in binding behavior. The N-glycan N80 is
situated in the SCR I-II interface and N49 on top of SCR I
(Fig. 5). Ablation of the N80-glycan led to a more than 10-fold
reduction of MV binding (25, 38), whereas for Ad35 we found
only a weak 2-fold reduction.
For Ad35, our mapping results in combination with the
three-dimensional structure of the outer SCR I!II fragment
(6) define a large, glycan-free surface formed by two flexibly
linked CD46 domains. The most distal SCR I domain contains
the critical residues K15, E24, R25, and K29 but not the cluster
of residues P39 to T44 (Fig. 5A to D [best seen in Fig. 5A]).
Weaker inhibition effects of the SCR I antibodies E4.3,
MCI20.6, and Tra-2 with critical residues E3, R48, and K17,
respectively, all located on the upper third of the SCR I do-
main, suggest that these sites are outside of the putative Ad35
binding area. The critical binding site in SCR II included the
Q88, Y106, Y98, and K119, as well as sites close to R69 and
E103, all located on the same surface (Fig. 5A to D [best seen
in Fig. 5D]). The latter two sites are defined by antibody M177
inhibition but not by single point mutations. Critical residues
N94 and Y97 are located on the face opposite to this binding
region. Since these residues are located at the low end of the
SCR II module, they may be involved in interdomain contacts
and exert an indirect effect on virus binding. Our data indicate
that the two putative Ad35 binding areas in SCR I and II of the
crystal structure are not exactly on the same side of the mol-
ecule but are twisted by about 90°. For MV, the mapping
results (4, 25, 40, 46) indicated a slightly shifted binding area
extending from near the top of the first to the bottom of the
second repeat, including the residues P39, K29, and E11 and
the residue clusters R25/D27 and R69/D70 of SCR I-II, all
located on the same side of the molecule (Fig. 5E to H [best
seen in Fig. 5F]). As in the case of Ad35, both domains are free
of carbohydrates and therefore are accessible for protein-pro-
tein interactions (6). The interdomain organization, which dif-
fers strikingly among the known SCR domain structures (6),
may be variable in solution. Indeed, when the three-dimen-
sional structure of the vaccinia virus complement control pro-
tein VCP was deduced, the molecule was found to have a rigid,
rod-like structure with no intramolecular contacts between
nonsequential modules but with a kink between modules I-III
and module IV (47). In contrast, a nuclear magnetic reso-
nance-derived structure of VCP SCR II-III alone indicated
flexibility between the modules (28). Based on the findings that
in RCA proteins more than one SCR domain is involved in
protein-protein interactions and that some degree of interdo-
main flexibility is allowed, it was suggested that the contact
surface between viruses and RCA receptors may consist not of
a single, narrow, and continuous binding site but rather of
several composite contact sites (4, 6). Such multimeric inter-
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actions result in higher avidity, thereby increasing affinity be-
tween otherwise low-affinity partners (66).
The length of the chimeric CD46-CD4 receptor molecules
modulates the efficiency of Ad35 uptake. In the case of MV,
inserting an increasing number of Ig-like modules as spacer
domains in the chimeric receptor gave a robust increase in MV
binding, but fusion efficiency, i.e., productive uptake, was un-
coupled and strongly reduced (5). Increased binding may be
due to reduction of steric hindrance resulting from moving the
binding site away from the membrane. For adenoviruses,
proper orientation of the receptor binding site towards the
viral ligand as well as secondary receptors can influence the
binding efficiency (reviewed in reference 68). In the context of
the virus particles, the length of the fiber protein influences the
efficiency of viral binding, as shown for the knob of the CAR
binding Ad5, which, when placed on the short shaft of another
Ad serotype, resulted in a reduction of virus attachment (60,
69). Here we found a robust increase of Ad35 transgene ex-
pression when using chimeric receptors with extended lengths,
although binding of Ad35 was not strongly influenced by the
CD46 length, suggesting that postbinding events depend on
proper spacing of viral attachment from the membrane.
The structure of the Ad3 fiber knob revealed an overall
shape very similar to that of CAR binding fiber heads, al-
though a more hydrophobic surface is exposed (13). No single
exclusive structural motif that disfavors binding to CAR could
be deduced, but rather several differences may account for the
receptor switch. The CAR binding site is located on the knob
side at the interface between two adjacent knob monomers. A
strong variation of the ligand binding residues, together with
water-filled cavities in the interface, resulting in a low topolog-
ical complementarity between the two molecules, is a special
feature of the Ad fiber-CAR receptor complex (2, 13). It will
be interesting to see whether binding of species B Ad knobs to
CD46 is based on similar structural features.
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